ASCO CONFERENCE COVERAGE
ASCO CONFERENCE COVERAGE
05/26/2026
Anthony Calabro, MA
In a phase 3 randomized trial of women with stage I-III breast cancer, a low-glycemic Mediterranean diet, brisk walking, and vitamin D did not reduce recurrence overall but improved weight and metabolic...
05/26/2026
ASCO CONFERENCE COVERAGE
ASCO CONFERENCE COVERAGE
05/26/2026
Anthony Calabro, MA
In a phase 3 randomized trial of women with stage I-III breast cancer, a low-glycemic Mediterranean diet, brisk walking, and vitamin D did not reduce recurrence overall but improved weight and metabolic...
05/26/2026
ASCO CONFERENCE COVERAGE
ASCO CONFERENCE COVERAGE
05/26/2026
Anthony Calabro, MA
In a phase 3 randomized trial of women with stage I-III breast cancer, a low-glycemic Mediterranean diet, brisk walking, and vitamin D did not reduce recurrence overall but improved weight and metabolic...
05/26/2026
ASCO CONFERENCE COVERAGE
ASCO CONFERENCE COVERAGE
05/26/2026
Anthony Calabro, MA
In a phase 3 randomized trial of women with stage I-III breast cancer, a low-glycemic Mediterranean diet, brisk walking, and vitamin D did not reduce recurrence overall but improved weight and metabolic...
05/26/2026
ASCO CONFERENCE COVERAGE
ASCO CONFERENCE COVERAGE
05/26/2026
Anthony Calabro, MA
In a phase 3 randomized trial of women with stage I-III breast cancer, a low-glycemic Mediterranean diet, brisk walking, and vitamin D did not reduce recurrence overall but improved weight and metabolic...
05/26/2026
ASCO CONFERENCE COVERAGE
ASCO CONFERENCE COVERAGE
05/26/2026
Anthony Calabro, MA
In a phase 3 randomized trial of women with stage I-III breast cancer, a low-glycemic Mediterranean diet, brisk walking, and vitamin D did not reduce recurrence overall but improved weight and metabolic...
05/26/2026
ASCO CONFERENCE COVERAGE
ASCO CONFERENCE COVERAGE
05/22/2026
Anthony Calabro, MA
In a propensity-matched analysis of stage I-III solid tumors, GLP-1 receptor agonist exposure after cancer diagnosis was associated with lower metastatic progression in several cancer types. These findings...
05/22/2026
ASCO CONFERENCE COVERAGE
ASCO CONFERENCE COVERAGE
05/22/2026
Anthony Calabro, MA
In a propensity-matched analysis of stage I-III solid tumors, GLP-1 receptor agonist exposure after cancer diagnosis was associated with lower metastatic progression in several cancer types. These findings...
05/22/2026
ASCO CONFERENCE COVERAGE
ASCO CONFERENCE COVERAGE
05/22/2026
Anthony Calabro, MA
In a propensity-matched analysis of stage I-III solid tumors, GLP-1 receptor agonist exposure after cancer diagnosis was associated with lower metastatic progression in several cancer types. These findings...
05/22/2026
ASCO CONFERENCE COVERAGE
ASCO CONFERENCE COVERAGE
05/22/2026
Anthony Calabro, MA
In a propensity-matched analysis of stage I-III solid tumors, GLP-1 receptor agonist exposure after cancer diagnosis was associated with lower metastatic progression in several cancer types. These findings...
05/22/2026